Microbiome and Sarcopenia in Patients With Liver Cirrhosis

Condition(s) studied

Investigational drug(s) / intervention(s)

Fresubin energy: dietary protein energy supplement

Study summary

Protein-energy malnutrition (PEM) occurs in 65-90% of patients with liver cirrhosis. Severity of malnutrition correlates with progression of liver disease and leads to sarcopenia in 30-70% of cirrhotic patients. Malnutrition and sarcopenia are associated with an increased risk of complications and mortality.

In cirrhosis the gut microbiome is altered leading to increased gut permeability, bacterial translocation and inflammation. Since the microbiome is involved in nutrient uptake and metabolism, it is hypothesized that microbiome alterations contribute to sarcopenia. A prospective controlled cohort study to investigate the interrelation of microbiome changes and sarcopenia in cirrhosis will be conducted. Furthermore the effect of nutritional interventions on the microbiome in cirrhosis will be studied. From this study information on how the gut microbiome composition and sarcopenia are associated in cirrhosis and if modulation of the gut microbiome by nutritional interventions is feasible will be collected.

Eligibility

Primary outcome measure(s)

• Alpha diversity — day 1
  16s rDNA sequencing of the stool microbiome

Trial sites (1)

More Medical University of Graz trials in Austria

Other trials for the same condition